Tolerability of Fluticasone Furoate/Vilanterol Combination Therapy in Children Aged 5 to 11 Years With Persistent Asthma

Abstract

Once-daily repeated dosing of FF/VI, 100/25 µg, using the ELLIPTA dry powder inhaler was as well tolerated as FF, 100 µg, in this small, selected population of 5- to 11-year-old, mostly white/caucasian children with persistent asthma.

New and future strategies to improve asthma control in children

“…Vilanterol is a LABA with 24-hour activity developed as a once-daily treatment in combination with a novel ICS, fluticasone furoate, approved by the FDA for the treatment of chronic obstructive pulmonary disease (COPD) in 2013 and for asthma in patients 18 years and older in 2015. [63][64][65] In patients 12 years and older with uncontrolled persistent asthma, there was no difference between 100/25 mg daily fluticasone furoate/vilanterol and 250/ 50 mg twice-daily fluticasone propionate/salmeterol in improvement in FEV 1 and time to onset of bronchodilator effect. 63 There was no difference in asthma exacerbations between fluticasone furoate/vilanterol and fluticasone propionate/salmeterol based on adverse event reporting.…”

Nutritional status, adiposity and asthma severity and control in children

“…In this study, we classified asthma severity as intermittent or persistent (mild, moderate and severe), based on NHLBI criteria. Such classification continues to be recommended by current asthma guidelines and widely used by recent studies of asthma . In the Australian Asthma Guideline, classification of asthma into intermittent and persistent refers to pattern of asthma rather than severity of disease.…”

“…Such classification continues to be recommended by current asthma guidelines 23,24 and widely used by recent studies of asthma. [25][26][27][28] In the Australian Asthma Guideline, 29 classification of asthma into intermittent and persistent refers to pattern of asthma rather than severity of disease. However, we believe that the pattern of a newly diagnosed asthma classified as intermittent and persistent mainly reflects the underlying severity of the disease.…”

The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma: clinical trial evidence and experience

“…The trial lasted a total of 11 weeks [Oliver et al 2014a]. The primary endpoints were peak expiratory flow rates (PEFs), blood pressure, clinical laboratory measurements, maximum heart rate and electrocardiogram (EKG) parameters.…”

“…The combination dosing of FF/VI was well tolerated and no significant differences were seen in the pharmacokinetic or pharmacodynamics of FF. No adverse events were judged to be serious or treatment related [Oliver et al 2014a] (Continued) more 24 h periods without use of rescue medication and without symptoms were reported with FF/VI compared with FF alone . No difference in AQLS scores or adverse events were noted.…”